# Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB1 Antagonist ANEB-001 in a THC Challenge Test

> **NCT05282797** · PHASE2 · COMPLETED · sponsor: **Anebulo Pharmaceuticals** · enrollment: 154 (actual)

## Conditions studied

- Acute Cannabinoid Intoxication

## Interventions

- **DRUG:** ANEB-001
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05282797
- **Lead sponsor:** Anebulo Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-15
- **Primary completion:** 2023-08-26
- **Final completion:** 2023-08-26
- **Target enrollment:** 154 (ACTUAL)
- **Last updated:** 2023-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05282797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05282797, "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB1 Antagonist ANEB-001 in a THC Challenge Test". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05282797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*